COMMUNIQUÉS West-GlobeNewswire

Data published in The New England Journal of Medicine demonstrate RYBREVANT®▼(amivantamab) plus LAZCLUZE®▼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer
07/09/2025
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one [...]
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
06/09/2025
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on [...]
Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community
06/09/2025
No-cost access available to qualified researchers via open-source federated data platform SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit [...]
Lygos Clinic lance des forfaits VIP tout compris pour le tourisme dentaire à destination des patients internationaux
06/09/2025
ISTANBUL, 06 sept. 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, centre dentaire de premier plan à Istanbul, a officiellement lancé ses nouveaux forfaits VIP tout compris de tourisme dentaire , conçus pour répondre à la [...]
CERN’s FPGA Failure and the Suppression of 3D-Flow and 3D-CBS: A Call to Save Millions of Lives and Billions of Euros
06/09/2025
After decades of outreach and evidence—never refuted—it is urgent to fund two 3D-CBS devices that could halve cancer deaths, and to support further press releases to inform taxpayers and decision-makers. No refutations [...]
RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
06/09/2025
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs 1 BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a [...]
Revive Therapeutics Announces Extension of Proposed Private Placement
06/09/2025
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/09/2025
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the [...]
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting [...]
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
05/09/2025
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
05/09/2025
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
05/09/2025
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards [...]
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq
05/09/2025
Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la [...]
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
05/09/2025
Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical- [...]

Pages